Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Letter to the Editor

Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”


Published online: October 30, 2026

Department of Laboratory Medicine, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, China

Corresponding author : Jice Wang Department of Laboratory Medicine, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, No. 182 Chunhui Road, Longmatan District, Luzhou, Sichuan 646000, China Tel: +86-830-2523233, Fax: +86-830-3160885, E-mail: lzmcwangjice@126.com

Editor: Gi-Ae Kim, Kyung Hee University, Korea

• Received: February 18, 2026   • Accepted: March 4, 2026

Copyright © 2026 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 249 Views
  • 6 Download
Dear Editor,
We read with great interest the study by Yoon et al. in Clinical and Molecular Hepatology [1]. The authors are to be commended for translating short-term histologic response (≥1-stage fibrosis regression) into pragmatic cost-effectiveness “response thresholds,” an approach that could meaningfully inform target product profiles, reimbursement criteria, and interpretation of modest absolute response differences in metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis drug development. Precisely because the manuscript’s central deliverable is a threshold intended for downstream clinical and policy use, internal consistency between the narrative conclusions and the supporting figures becomes essential for clinical actionability.
First, the manuscript conveys mixed messages regarding the logical definition of the cost-effectiveness threshold. In the Study Highlights and Abstract, cost-effectiveness is framed as requiring both an initial regression gap of at least 15% and a minimum sustained durability gap of 3%. In contrast, the Results text describing the two-way sensitivity analysis indicates that “over 10%” initial gap with a 3% minimum durability is cost-effective. The Discussion then introduces an “OR” formulation, stating that the drug needs a minimum of 15% or higher initial response rates or a minimum sustained durable response of 3%. These shifts are not merely semantic: moving from “15% AND 3%” to “10% AND 3%,” or to “15% OR 3%,” fundamentally changes the implied bar for clinical development and payer acceptance. In practice, clinicians, trialists, and payers use such thresholds as simplified decision heuristics; inconsistent logic can therefore alter how therapies are judged as “viable,” how effect-size expectations are set in trials, and how clinicians counsel institutions and patients about whether an agent is likely to meet value-based benchmarks.
Second, the most clinically salient concern is that the narrative threshold appears inconsistent with the boundary displayed in Figure 3 of Yoon et al. [1], making the discrepancy readily verifiable and potentially consequential for interpretation. Figure 3 of Yoon et al. [1] visually supports a frontier-type relationship in which durability can compensate for a modest initial response, and vice versa, with the “not cost-effective” region seemingly confined to the joint minimum tested values (10% initial gap paired with 2% minimum durability). A rigid narrative statement such as “must be ≥15%” risks undervaluing drug profiles characterized by durable benefit but modest initial efficacy, while also risking overvaluation of profiles with strong early response but limited durability, both of which have direct clinical implications when selecting candidates for treatment and planning follow-up. If the intended message is a trade-off frontier rather than a single universal cutoff, the manuscript would be more clinically actionable by stating conditional rules (or tabulating the grid combinations crossing the willingness-to-pay threshold) and using consistent AND/OR logic throughout the Highlights, Abstract, Results, and Conclusions.
Third, the South Korea scenario analysis contains a clear “respectively” mapping issue in the currency conversion: daily costs of $7.65, $9.56, and $11.47 are stated to correspond, respectively, to approximately ₩12,500, ₩10,000, and ₩15,000, which inverts the expected ordering for the first two values. While this may appear minor, it can have an outsized downstream impact because regional scenario results are frequently extracted into local policy briefs, affordability assessments, and pricing negotiations. An incorrect USD-to-KRW mapping can mislead stakeholders regarding the implied daily price point at which the intervention is considered attractive in the Korean setting. Correcting the mapping and explicitly stating the exchange rate and costing year would strengthen the credibility and usability of the regional conclusions.
In summary, the conceptual contribution of linking short-term fibrosis regression to long-term value is timely and potentially influential. However, because the main product is a “threshold,” inconsistent logical operators across sections, discordance with Figure 3 of Yoon et al. [1], and the KRW conversion error could lead to avoidable misinterpretation in clinical development, reimbursement discussions, and cross-country translation. A brief clarification (and, if needed, an erratum) aligning the written thresholds with Figure 3 of Yoon et al. [1] and correcting the currency mapping would substantially improve the manuscript’s clinical actionability and policy relevance.

Authors’ contribution

Jice Wang: Manuscript conception and writing.

Conflicts of Interest

No conflicts of interests or personal relationships.

  • 1. Yoon EL, Cho JY, Park H, Kim M, Park JH, Kim HL, et al. Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2026;32:276-288.

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”
Close
Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”
Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”